Opportunities and Challenges for Generic Drugs in the UK

Table of Contents

Foreword

Introduction

Background to the Market

• Geography
• Political Overview
• Economic Overview
• Demographics
  • Demographic indicators
• The UK Healthcare System
  • Organisation
    • Primary Care Trusts
  • Healthcare expenditure
  • Hospital beds
  • Medical personnel

The UK Generics Market

• In Context: the UK Pharmaceutical Market
  • Market Structure
  • Reimbursement
  • Pricing: the PPRS
  • Unbranded Generic Pricing
    • 2005 generics reimbursement scheme
    • Generic price reductions for four major drugs
    • DOH Holds consultations regarding branded generics in the PPRS
  • Regulation of Pharmaceuticals
    • Generic regulation
  • Intellectual Property
    • Supplementary Protection Certificates
  • Prescription Medicines Market
    • England
• Generic Market Size
  • Generic Prescribing
    • Scotland
    • Wales
• Outlook for Future Growth
  • Investigations into price fixing
    • Department of Health
    • Ranbaxy and Merck settle DOH claims
    • Serious Fraud Office
• Overview of the Domestic Industry
  • Total Turnover
  • UK Turnover
  • Operating Profit
  • Net Profit
  • Employees
  • Sales per Employee
• Leading Players in the Market
  • Actavis UK Ltd
    • Actavis worldwide
    • Actavis in the UK
    • Products on the UK market
    • Financial indicators
  • Arrow Generics Ltd
    • Products on the UK market
    • Financial indicators
  • Bristol Laboratories
    • Products on the UK Market
    • Financial indicators
  • Crescent Pharma
    • Products on the UK market
    • Financial indicators
  • Dr Reddy' s Laboratories (UK) Ltd
    • Dr Reddy' s worldwide
    • UK operations
    • Financial indicators
  • Focus Pharmaceuticals
    • Products in the UK
    • Financial Indicators
  • Generics (UK) Ltd
    • Merck Generics worldwide
    • UK Operations
    • Products in the UK market
    • Financial indicators
  • Genus Pharmaceuticals
    • Products
    • Financial indicators
  • Goldshield Pharmaceuticals Ltd
    • Goldshield Group
    • Products
    • Financial indicators
  • Kent Pharmaceuticals
    • Products
    • Financial indicators
  • Perrigo UK Ltd
    • Products
    • Financial indicators
  • Pliva Pharma Ltd
    • Pliva worldwide
    • Pliva in the UK
    • Financial indicators
  • Ranbaxy (UK) Ltd
    • Ranbaxy worldwide
    • Ranbaxy in the UK
    • Financial indicators
  • ratiopharm UK
    • ratiopharm worldwide
    • ratiopharm in the UK
    • Financial indicators
  • Rosemont Pharmaceuticals
    • Products
    • Financial indicators
  • Sandoz
    • Sandoz worldwide
    • Sandoz in the UK
    • Products
    • Financial indicators
  • Teva UK
    • Teva worldwide
    • Teva in the UK
    • Financial indicators
  • Winthrop Pharmaceuticals
    • Winthrop worldwide
    • Winthrop in the UK
    • Products
    • Financial indicators
  • Wockhardt UK Ltd
    • Wockhardt worldwide
    • Wockhardt in the UK
    • Products
    • Financial indicators
  • Marketing Authorisations in 2006
  • Trading Companies
  • Wholesaling
    • AAH Pharmaceuticals Ltd
    • Alliance Boots (formerly Alliance Unichem)
      • Exclusive Distribution Deal with Pfizer
    • Mawdsleys
    • Phoenix Healthcare Distribution Ltd
  • Retailing
    • Major Pharmacy Chains
      • Alliance Boots
    • Lloyds Pharmacy
    • Superdrug

Appendix 1: Analysis of Leading Patent-Expired Drugs

• Amisulpride
• Risperidone
• Ramipril
• Glimepiride
• Ondansetron
• Sumatriptan
• Amlodipine
• Citalopram
• Fluconazole
• Gabapentin
• Lamotrigine
• Meloxicam
• Meloxicam
• Sertraline
• Tamsulosin
• Terbinafine

Appendix 2: Rising Use of Generics in the UK Statins Market

• Market Developments
• Atorvastatin
• Fluvastatin
• Pravastatin
• Rosuvastatin
• Simvastatin

Appendix 3: Generics in the UK PPI Market

• Esomeprazole
• Lansoprazole
• Omeprazole
• Pantoprazole
• Rabeprazole sodium

Appendix 4: Sources

• Espicom Sources
• UK Government Sources
• Industry Sources

Appendix 5: DIRECTORY

• Regulators
• Trade Bodies
• Manufacturers